Regulus (RGLS) Therapeutics announced positive clinical and regulatory updates from its ADPKD program. The update includes positive topline results from an interim analysis of the fourth cohort of ...

ADPKD, or autosomal dominant polycystic kidney disease, can cause severe pain, headaches, and more problems. What can you do to feel better and stay active? Find exercise and diet tips ...

Before receiving a kidney transplant, patients with autosomal dominant polycystic kidney disease often undergo a nephrectomy. But there hasn’t been clear guidance on who’s a good candidate ...

Buoyed by encouraging data for its lead drug for autosomal dominant polycystic kidney disease, Regulus Therapeutics has moved swiftly to file a financing that will give it the finances needed to ...

Autosomal dominant polycystic kidney disease rates in the Military Health System are comparable to the general population, ...

Clinicians should monitor patients with stones, even if they are asymptomatic, to slow kidney function decline, investigators suggest. Even asymptomatic kidney stones may spur kidney function ...

"Even more encouraging is the repeated demonstration across multiple cohorts in the trial that, on average, growth of the kidney in ADPKD patients is halted after only a relatively short ...

Farabursen 300 mg showed a mean htTKV growth rate of 0.05% vs. 2.58% in placebo, indicating a potential impact on ADPKD progression. Urinary PC1 and PC2 levels increased significantly, consistent ...

A multicenter study from the Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease has furthered understanding of the relationship between rates of kidney enlargement and decline ...

Rege Nephro Co., Ltd. (Headquarter: Kyoto, Japan; Chief Executive Officer: Akifumi Morinaka) has announced that it has successfully acquired Tamibarotene-related clinical and non-clinical assets from ...